NCT00569127 2026-03-18
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
84 trialsNCT03375320 2026-03-18
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07087054 2026-03-10
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3 Recruiting
NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT06784752 2026-03-06
NETTER-3
Novartis
Phase 3 Recruiting
NCT03194893 2026-02-20
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06822751 2026-02-17
FOMUTI
University Hospital, Rouen
Phase 3 Not yet recruiting
NCT06937905 2026-02-11
TARLANEC
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Recruiting
NCT04706910 2026-02-09
18F-DOPA II - PET Imaging Optimization
University of Alberta
Phase 3 Recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT06881992 2025-12-30
Tumor HI
Rezolute
Phase 3 Recruiting
NCT04940052 2025-12-02
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Novartis
Phase 3 Active not recruiting
NCT03872401 2025-11-10
VESALIUS-CV
Amgen
Phase 3 Completed
NCT05050942 2025-11-06
SORENTO
Camurus AB
Phase 3 Active not recruiting
NCT03690388 2025-09-25
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
Phase 3 Active not recruiting
NCT00410761 2025-09-24
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sanofi
Phase 3 Completed
NCT07185672 2025-09-22
PReCedeNT
Tata Memorial Hospital
Phase 3 Recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT05387603 2025-09-10
START-NET
Lund University Hospital
Phase 3 Recruiting
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT03697109 2025-07-16
GRACE
Corcept Therapeutics
Phase 3 Completed
NCT02010957 2025-06-10
FAMIAN
Wuerzburg University Hospital
Phase 3 Terminated
NCT06091748 2025-06-03
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT03049189 2025-05-30
COMPETE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT02437318 2025-02-13
SOLAR-1
Novartis
Phase 3 Completed
NCT06791005 2025-01-24
A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.
Second Affiliated Hospital of Xi'an Jiaotong University
Phase 3 Recruiting
NCT00924989 2024-11-20
GALACCTIC
Astellas Pharma Inc
Phase 3 Completed
NCT03723941 2024-08-01
ACACIA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT04847505 2024-07-18
68Ga-DOTA-TATE PET/CT Imaging in NETs
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Phase 3 Recruiting
NCT02422615 2023-11-30
MONALEESA-3
Novartis
Phase 3 Completed
NCT03176693 2023-11-20
Preoperative Alpha Blockade for Pheochromocytoma
University of California, Los Angeles
Phase 3 Completed
NCT04964284 2023-10-23
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01837745 2023-05-17
ESTIMABL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Active not recruiting
NCT03136328 2023-05-09
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Montefiore Medical Center
Phase 3 Completed
NCT03048877 2023-04-12
Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 3 Unknown
NCT02588170 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT02589821 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT03673943 2022-12-22
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
Radiomedix, Inc.
Phase 3 Completed
NCT05647954 2022-12-13
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
Taizhou Hanzhong biomedical co. LTD
Phase 3 Unknown
NCT01842165 2022-11-10
LUMEN
Jules Bordet Institute
Phase 3 Completed
NCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT00842348 2022-10-12
NET729
Ipsen
Phase 3 Completed
NCT02683941 2022-07-06
SPINET
Ipsen
Phase 3 Terminated
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT02419664 2022-03-31
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Göteborg University
Phase 3 Terminated
NCT03042416 2022-01-10
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
University of Alberta
Phase 3 Completed
NCT03602495 2021-12-13
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Terminated
NCT01524783 2021-08-05
RADIANT-4
Novartis
Phase 3 Completed